Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 2/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134519 | 0.94 | TSHR (0.42) | EP300TSHRFAAHTRPV1ALDH1A1 | |
| SCHEMBL4130593 | 0.85 | — | — | |
| SCHEMBL9950817 | 0.79 | EP300 (0.44) | EP300TSHRFAAHMEN1CYP3A4 | |
| SCHEMBL11461319 | 0.76 | EP300 (0.43) | EP300TSHRTRPV1MEN1CYP3A4 | |
| SCHEMBL11461320 | 0.76 | EP300 (0.43) | EP300TSHRTRPV1MEN1CYP3A4 | |
| SCHEMBL11801529 | 0.76 | EP300 (0.48) | EP300TSHRFAAHTRPV1MEN1 | |
| SCHEMBL11693855 | 0.76 | EP300 (0.48) | EP300TSHRFAAHTRPV1MEN1 | |
| SCHEMBL4952458 | 0.75 | EP300 (0.48) | EP300FAAHALDH1A1MEN1CYP3A4 | |
| SCHEMBL4952452 | 0.75 | EP300 (0.48) | EP300FAAHALDH1A1MEN1CYP3A4 | |
| SCHEMBL4142094 | 0.73 | EP300 (0.42) | EP300TSHRFAAHTRPV1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090099216-A1 | NOVEL ADENINE COMPOUND | ASTRAZENECA AKTIEBOLAG A CORPORATION OF SWEDEN (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1939198-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939200-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939201-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | EP300 1419/4885TSHR 2895/4885FAAH 2347/4885 |
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | EP300 2214/4885TSHR 3415/4885FAAH 2884/4885 |
| US-20090099216-A1 | NOVEL ADENINE COMPOUND | ADORA1, CXCR6, NR0B1 | EP300 706/4885TSHR 1269/4885FAAH 3442/4885 |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | XDH, ADORA1, NUDT1 | EP300 967/4885TSHR 3563/4885FAAH 3047/4885 |
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | ADORA1, SLC28A1, ADORA2A | EP300 2341/4885TSHR 3960/4885FAAH 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.